By Sabela Ojea

GlaxoSmithKline PLC said Tuesday that its drug Daprodustat has received marketing authorization by the European Medicines Agency.

The company said its application was accepted for review by the EMA.

The drug Daprodustat, aimed at treating anaemia of chronic kidney disease, is currently approved in Japan, the FTSE 100-listed company said.

Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix

(END) Dow Jones Newswires

March 01, 2022 02:27 ET (07:27 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more GSK Charts.
GSK (NYSE:GSK)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more GSK Charts.